GOG 3016/ENGOT-cx9: An open-label, multi-national, randomized, phase III trial of cemiplimab, an anti-PD-1, versus investigator's choice (IC) chemotherapy in ≥ second-line recurrent or metastatic cervical cancer

Journal Article (Journal Article)

Full Text

Duke Authors

Cited Authors

  • Tewari, KS; Vergote, I; Oaknin, A; Alvarez, E; Gaillard, S; Lheureux, S; Rischin, D; Santin, AD; Feng, M; Mathias, M; Fury, M; Lowy, I; Monk, BJ

Published Date

  • November 1, 2018

Published In

Volume / Issue

  • 29 /

Start / End Page

  • ix86 -

Electronic International Standard Serial Number (EISSN)

  • 1569-8041

Digital Object Identifier (DOI)

  • 10.1093/annonc/mdy436.027

Citation Source

  • Scopus